Gastroenterology

Dr. Neil Sharma Joins Peak Gastroenterology Associates in Colorado Springs

Retrieved on: 
Monday, January 8, 2024

Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today welcomed Neil Sharma, MD, one of the nation’s leading board-certified, fellowship-trained interventional gastroenterologists and endoscopists.

Key Points: 
  • Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today welcomed Neil Sharma, MD, one of the nation’s leading board-certified, fellowship-trained interventional gastroenterologists and endoscopists.
  • Dr. Sharma will lead Peak’s interventional program in Colorado Springs, Colorado.
  • Dr. Sharma joins Peak from Parkview Health, northeast Indiana’s largest not-for-profit healthcare provider, where he served for over 10 years, most recently as the first President of the Parkview Cancer Institute, which he helped to conceive and develop.
  • He went on to pursue an additional fellowship in Interventional Endoscopy at the University of North Carolina, Chapel Hill.

Mercy Announces New Leaders to Enhance Services in Neurosciences, Surgery and GI, Women and Children

Retrieved on: 
Monday, January 8, 2024

These new leaders will improve patient access across Mercy, while developing impactful strategies, identifying areas for investment and improving performance.

Key Points: 
  • These new leaders will improve patient access across Mercy, while developing impactful strategies, identifying areas for investment and improving performance.
  • Connor, who now leads neurosciences, brings experience from his role as chief operating officer at Health First in Melbourne, Florida.
  • This strategic approach will provide our patients with increased access to low-cost, high-quality health care services everywhere that Mercy serves."
  • Mercy is actively interviewing candidates for the final service line president position in cardiovascular care, reinforcing the commitment to comprehensive and integrated health care services.

Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

Retrieved on: 
Monday, January 8, 2024

WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update on the company’s progress in 2023 and initial expectations for 2024.

Key Points: 
  • “2023 was a landmark year for Ardelyx, marking our first full year as a commercial entity and the approval and launch of our second first-in-class product.
  • XPHOZAH® joins IBSRELA in our portfolio of important treatment options for patients with unmet needs,” said Mike Raab, president and chief executive officer.
  • We are poised to continue with a growth trend in 2024.
  • Ardelyx currently expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.

Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions

Retrieved on: 
Thursday, January 4, 2024

DURHAM, N.C. , Jan. 4, 2024 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, today announced its innovative Precision Medicine Platform, a robust biorepository of 150,000+ samples collected along the patient journey from over 10,000 enrolled patients with 5+ years of clinical follow-up. Combined with Target RWE's longitudinal clinical registry data, the biorepository can be instrumental in genetic and bio-marker identification for patient populations with rapid disease progression or prediction of treatment response.

Key Points: 
  • In the TARGET-NASH registry alone, 80,000+ biospecimen samples have been collected by Target RWE.
  • Target RWE concentrates on disease areas with high unmet medical needs and emerging therapies.
  • This includes a focus on liver disease, metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NAFLD/NASH), and immune-mediated inflammatory conditions in dermatology and gastroenterology.
  • Visit our website to learn more about Target RWE and our precision medicine solutions.

Pylo Health Launches Next Generation of Cellular-Connected Remote Patient Monitoring Devices

Retrieved on: 
Thursday, January 4, 2024

INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Pylo Health , a leading provider of remote patient monitoring devices and partner company to Prevounce , announces the launch of two next-generation patient devices: the Pylo 900-LTE blood pressure monitor and the Pylo 200-LTE weight scale.

Key Points: 
  • INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Pylo Health , a leading provider of remote patient monitoring devices and partner company to Prevounce , announces the launch of two next-generation patient devices: the Pylo 900-LTE blood pressure monitor and the Pylo 200-LTE weight scale.
  • The 900-LTE is Pylo's latest blood pressure monitor for patients enrolled in remote patient monitoring (RPM) programs for hypertension and related chronic conditions.
  • Both Pylo devices and their packaging are designed for easy customization, allowing for the addition of logos, taglines, patient inserts, and more.
  • Contact Pylo if you are affiliated with a medical practice, health system, or payer interested in learning more about the 900-LTE, 200-LTE, or other RPM devices.

Nearly 100 Physicians from MemorialCare's Long Beach Medical Center, Miller Children's & Women's Hospital Long Beach Recognized by Leading Doctor's Report

Retrieved on: 
Wednesday, January 3, 2024

LONG BEACH, Calif., Jan. 3, 2024 /PRNewswire/ -- MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach had 86 physicians named Super Doctors and 11 as Rising Stars by the 2023 Southern California Super Doctors & Rising Stars report The Southern California Super Doctors report lists the most outstanding doctors for more than 40 medical specialties, most of whom are in the top 5% of physicians.

Key Points: 
  • LONG BEACH, Calif., Jan. 3, 2024 /PRNewswire/ -- MemorialCare's Long Beach Medical Center and Miller Children's & Women's Hospital Long Beach had 86 physicians named Super Doctors and 11 as Rising Stars by the 2023 Southern California Super Doctors & Rising Stars report The Southern California Super Doctors report lists the most outstanding doctors for more than 40 medical specialties, most of whom are in the top 5% of physicians.
  • The 2023 Southern California Super Doctors report recognizes the top five percent of active doctors in Los Angeles County with two lists: Super Doctors 2023 and Rising Stars.
  • "Having our physicians listed in the Super Doctors and Rising Stars reports highlight the professionalism of our physicians who have attained a high degree of peer recognition and professional achievement," says Joe Kim, M.D., chief medical officer, MemorialCare Long Beach Medical Center.
  • "Our physicians consistently offer exceptional, quality-driven, family-centered care to our patients and families," says Graham Tse, M.D., chief medical officer, MemorialCare Miller Children's & Women's Hospital Long Beach.

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

Retrieved on: 
Wednesday, January 3, 2024

The event is being held at Convene, located at 100 Stockton Street, San Francisco, Calif. and will be webcast live.

Key Points: 
  • The event is being held at Convene, located at 100 Stockton Street, San Francisco, Calif. and will be webcast live.
  • A link to the webcast can be accessed on the Investors section of the company's website at www.ardelyx.com .
  • The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.
  • IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD

Retrieved on: 
Wednesday, December 20, 2023

PPI-nrsGERD affects over 20 million patients in the U.S., and current treatments are focused solely on the mechanism of acid suppression without addressing gastrointestinal (GI) motility.

Key Points: 
  • PPI-nrsGERD affects over 20 million patients in the U.S., and current treatments are focused solely on the mechanism of acid suppression without addressing gastrointestinal (GI) motility.
  • “Naronapride is a potential best-in-class pan-GI prokinetic which is currently in a multi-center Phase 2b study in patients with gastroparesis.
  • It has completed four Phase 2 studies in related GI indications including as monotherapy in newly diagnosed GERD.
  • “We look forward to collaborating with the Agency to demonstrate naronapride is both safe and effective for PPI-nrsGERD.”

US Digestive Health Expands Access to Advanced Gastroenterology Care Through its Partnership with Southwest Gastroenterology Associates (SWGA)

Retrieved on: 
Tuesday, December 19, 2023

EXTON, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the largest gastroenterology practices in the United States, managed by US Digestive Health Management (USDHM), a management services organization created to expand access to high-quality, low-cost gastroenterology care, today announced the addition of Southwest Gastroenterology Associates (SWGA), further expanding its comprehensive gastroenterology care services in Pennsylvania.

Key Points: 
  • EXTON, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the largest gastroenterology practices in the United States, managed by US Digestive Health Management (USDHM), a management services organization created to expand access to high-quality, low-cost gastroenterology care, today announced the addition of Southwest Gastroenterology Associates (SWGA), further expanding its comprehensive gastroenterology care services in Pennsylvania.
  • “Southwest Gastroenterology has established itself as a trusted provider of high-quality, compassionate digestive health services in the region by delivering personalized care for its patients,” said Jerry Tillinger, CEO of USDHM.
  • US Digestive Health remains dedicated to upholding its reputation as a leading provider of digestive health services in the Northeastern United States.
  • US Digestive Health Management works hand in hand with gastroenterology partner practices to meet the challenges inherent in the fast-changing healthcare landscape.

Acino completes acquisition of M8 Pharmaceuticals significantly expanding presence and capabilities in Latin America

Retrieved on: 
Monday, December 4, 2023

This acquisition provides Acino with access to the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region.

Key Points: 
  • This acquisition provides Acino with access to the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region.
  • Integration of the M8 portfolio, pipeline, and operations with Acino is underway while both businesses continue to focus on their day-to-day operations.
  • Andrew Bird, Interim CEO at Acino commented: “I am delighted to complete this transformational deal for Acino.
  • I extend a warm welcome to nearly 300 new colleagues at M8 who have now joined the Acino family.”
    Joel Barlan, CEO at M8 commented: “Today marks an exciting new chapter for M8 and Acino.